M2 Pharma - Therapy Areas

Northwest Biotherapeutics presents updated DCVax-L Phase III trial survival data for glioblastoma

9 July 2026 - Northwest Biotherapeutics (OTCQB:NWBO)(NWBio), a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers, announced on Wednesday that the company�...

HanchorBio plans combination research with late-stage cancer drug resistance specialist InxMed

9 July 2026 - Taiwan-listed clinical-stage biotech HanchorBio Inc (TWSE:7827) announced on Wednesday that it is looking to broaden the development path for HCB101, its lead oncology asset, through a n...

GE HealthCare and Mayo Clinic launch prostate cancer theranostics research study

8 July 2026 - Healthcare solutions provider GE HealthCare Technologies Inc (NASDAQ: GEHC) and non-profit organisation Mayo Clinic announced on Wednesday the launch of the MI-BET (Molecular Imaging Bio...

Physiomics secures new contracts worth over GBP200,000

8 July 2026 - Physiomics plc (AIM: PYC), a mathematical modelling, data science and biostatistics company, declared on Wednesday that it has secured multiple contract awards with a combined estimated ...

Wiley announces launch of Advanced Immunology open access journal

8 July 2026 - Wiley (NYSE: WLY), a provider of content and research intelligence, announced on Tuesday that it has launched Advanced Immunology, a new open access journal focused on basic, clinical an...

EDX Medical to provide molecular profiling services to Astron Health

8 July 2026 - EDX Medical Group plc (LSE: EDX) announced on Wednesday that it has been appointed by Astron Health Ltd to provide molecular profiling products and services in the UK, expanding its prec...